Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

Kardashian Barker discusses the brand’s latest hair growth and anti-shedding capsule launch, her current post-pregnancy hair ...

The citrus bioflavonoids market is projected to grow from $1.08 billion in 2023 to $1.2 billion in 2024, at a CAGR of 10.6%. Increased consumer interest in natural health products, the expanding use ...

Lemme’s new supplement is named GLP-1 Daily - a direct reference to the Ozempic hormone. It is designed to “reduce body weight, visceral fat, and hip and waist circumference”, according to ...

GLP-1 receptor agonist use in the perioperative period should be based on shared decision-making of patient and care teams. (HealthDay News) — In a multisociety clinical practice guidance ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Intense competition from Viking Therapeutics and Amgen, may result in a new best in class GLP-1 drug, further threatening Novo's moat. The Company's valuation remains high at 33.2x forward ...

Lexaria’s strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a ...

Image: Pixabay Mumbai: Dr. Reddy’s Laboratories Ltd aims to have about 15 GLP-1 drugs, used to treat obesity and diabetes, in its portfolio with various timelines, the pharma major’s chief ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug ...

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron that will start dose optimisation studies later ...